
Releases
Investors Face August Deadline in ADMA Biologics Securities Lawsuit
Investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, have until August 10, 2026, to seek lead plaintiff status in a class action lawsuit. The litigation, filed in New Jersey, accuses the biopharmaceutical company of inflating revenue through undisclosed related-party transactions and channel stuffing.




























